ATAI

AtaiBeckley Inc. Common Stock

$7.35

+0.82%
Sep 10, 2026
Bobby Quantitative Model
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing rapid-acting, convenient mental health treatments, with a pipeline that includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCl) for social anxiety disorder, all currently in Phase 2 development. As a small-cap, pre-revenue biotech with only 99 employees, it is a niche, science-driven player rather than a commercial-stage platform, and its identity is defined by the psychedelic-derived mechanism of its assets rather than by marketed products. The dominant investor narrative has been transformed by Eli Lilly's acquisition of AtaiBeckley at a premium, a deal that validates the company's novel depression therapy and offers shareholders a defined exit, as reported in July 2026. That event has shifted the debate from clinical-trial probability and cash runway to deal-certainty, arbitrage spread, and the possibility of a competing bid, which explains the stock's sharp re-rating and its unusually tight trading range in recent weeks.

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Moderna

Moderna

MRNA

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis

BobbyInvestment Opinion: Should I buy ATAI Today?

The synthesized recommendation is Hold. The core thesis is that the stock is fairly valued around the pending acquisition by Eli Lilly, with limited upside to the consensus target of $8.10 (+10.2%) and significant downside if the deal fails. The analyst consensus target of $8.10 and the low target of $7.45 anchor the view, suggesting the market has already priced in the base-case deal outcome.

Supporting evidence includes the extreme valuation multiples: PS of 226.59x and EV/Sales of 560.02x, which are not justified by current fundamentals but reflect the acquisition premium. Revenue growth cannot be assessed from the provided data, but the analyst estimated revenue average of $215.2 million implies a future commercial ramp. Profitability is deeply negative with EPS of -$0.71 and net margin of -161.42%, though the gross margin of 75.25% is high for a biotech. The strong balance sheet (current ratio 11.74, debt-to-equity 0.0093) reduces solvency risk, but the negative ROE of -297.49% shows capital is being consumed. The implied upside to the average target is only 10.2%, which is modest relative to the risk.

The biggest risks are deal failure, valuation compression, and high volatility. The stock would likely drop to the pre-deal price of $5.36 (-27%) if the acquisition breaks, and could fall to the 52-week low of $3.265 (-55.6%) in a severe scenario. The rating would upgrade to Buy if a competing bid emerges above $9.25 or if the deal closes and the pipeline shows standalone promise. It would downgrade to Sell if the deal is terminated or if regulatory hurdles arise. Relative to its history and peers, the stock appears overvalued on a fundamental basis, but fairly valued as a merger-arbitrage play. Investors should consider the risk-reward as balanced but skewed to the downside given the tight spread to the low target.

Sign up to view all

ATAI 12-Month Price Forecast

The stock is in a merger-arbitrage phase, with the price anchored near the deal value and limited upside to the analyst average target of $8.10. The bull case relies on a competing bid or sweetened offer, while the bear case hinges on deal failure, which could cause a 27-55% decline. The valuation is extreme on a fundamental basis, but the acquisition provides a floor. I would upgrade to bullish if a competing bid emerges above $9.25, and downgrade to bearish if the deal faces regulatory hurdles or is terminated. Given the balanced risk-reward and moderate analyst conviction, a neutral stance is appropriate.

Historical Price
Current Price $7.35
Average Target $7.78
High Target $9.25
Low Target $3.27

Wall Street consensus

Most Wall Street analysts maintain a constructive view on AtaiBeckley Inc. Common Stock's 12-month outlook, with a consensus price target around $8.12 and implied upside of +10.4% versus the current price.

Average Target

$8.12

0 analysts

Implied Upside

+10.4%

vs. current price

Analyst Count

—

covering this stock

Price Range

$7 - $9

Analyst target range

Seven analysts cover ATAI, with a consensus average target price of $8.10, implying roughly +10.2% upside from the current price of $7.35; the recommendation field is listed as "none," so a formal Buy/Hold/Sell distribution is not available, but the target skew suggests a mildly bullish to neutral stance anchored by the pending acquisition. The consensus target of $8.10 sits above the current price but below the high target, indicating analysts see modest additional value beyond the deal price, likely reflecting either a probability-weighted competing bid or time value. Estimated EPS averages of -$0.196 (range -$0.389 to -$0.081) show analysts expect losses to narrow sharply, which supports the constructive tone. The target range spans $7.45 (low) to $9.25 (high), a spread of $1.80, or about 24% of the low end, which signals moderate rather than high conviction. The low target of $7.45 essentially equals the 52-week high and implies the market is already pricing the base-case deal outcome with little residual upside, while the high target of $9.25 assumes either a sweetened offer, a competing bid, or successful standalone pipeline progress that re-rates the equity. Because the low target is only marginally above the current price, the risk-reward is asymmetric to the downside if the deal were to break, even though the average target implies upside. No institutional ratings data was provided, so recent upgrade/downgrade patterns cannot be assessed; the relatively tight $7.45-$9.25 range nonetheless suggests analysts view the outcome as largely binary around the acquisition rather than driven by independent clinical catalysts.

Drowning in data?

Find the real signal!

Bulls vs Bears: ATAI Investment Factors

The bull case rests on the Eli Lilly acquisition, which provides a defined exit at a premium and has driven the stock up 87.5% over three months. Analyst targets imply modest upside to $8.10 on average, and the strong balance sheet (current ratio 11.74, debt-to-equity 0.0093) minimizes solvency risk. However, the bear case highlights extreme valuation multiples (PS 226.59x, EV/Sales 560.02x) and the risk that the deal could break, which would likely cause a sharp reversion toward the pre-deal price of $5.36. The most important tension is deal certainty versus deal risk: if the acquisition closes as expected, the stock is fairly valued with limited upside; if it fails, the downside is substantial. Currently, the bull evidence is stronger due to the announced acquisition and analyst targets above the current price, but the risk-reward is asymmetric to the downside given the tight spread to the low target.

Bullish

  • Lilly Acquisition Provides Defined Exit: Eli Lilly's acquisition of AtaiBeckley at a premium, reported July 16, 2026, validates the company's novel depression therapy and offers shareholders a clear exit. The stock gapped from $5.36 on July 15 to $7.15 on July 16, a 33% jump, and has since consolidated tightly around $7.18-$7.44, reflecting deal certainty.
  • Analyst Targets Imply Further Upside: The consensus average target price of $8.10 implies +10.2% upside from the current $7.35, with a high target of $9.25 suggesting potential for a sweetened or competing bid. The low target of $7.45 is only marginally above the current price, indicating limited downside if the deal closes as expected.
  • Strong Balance Sheet Reduces Solvency Risk: With a current ratio of 11.74 and debt-to-equity of just 0.0093, the company carries almost no leverage and has ample short-term liquidity. This financial cushion minimizes the risk of a cash crunch before the acquisition completes.
  • Momentum and Relative Strength Persist: The stock is up 55.72% over one year and 99.19% over six months, with relative strength versus SPY of +84.46 over three months. This sustained outperformance reflects the market's confidence in the deal and the underlying pipeline.

Bearish

  • Extreme Valuation Metrics: The price-to-sales ratio is 226.59x and EV/Sales is 560.02x, both far above typical clinical-stage biotech levels. These multiples are not supported by current fundamentals and reflect the acquisition premium embedded in the share price, leaving little room for error.
  • Deal Risk and Arbitrage Spread: The stock trades at $7.35, just 1.3% below the 52-week high of $7.45 and only 1.3% below the analyst low target of $7.45. If the acquisition were to break, the downside could be severe, as the pre-deal price was around $5.36, implying a potential 27% drop.
  • Negative Profitability and Cash Burn: Trailing EPS is -$0.71, net margin is -161.42%, and ROE is -297.49%, indicating the company is deeply unprofitable and consumes capital. With no positive free cash flow, it relies on external financing, though the acquisition may eliminate this need.
  • High Volatility and Short Interest: Beta is 1.552, meaning the stock is 55% more volatile than the market, and the short ratio is 2.84, indicating a meaningful short base that could amplify moves if deal news turns negative. The max drawdown of -48.06% shows how severe prior selloffs have been.

ATAI Technical Analysis

ATAI is in a powerful, sustained uptrend, with a 1-year price change of +55.72% and a 6-month gain of +99.19%, and at a current price of $7.35 it sits at roughly 98.5% of its 52-week range (52-week low $3.265, 52-week high $7.45). That positioning near the top of the annual range signals strong momentum but also leaves little room for upside before hitting the high, meaning the stock is trading in a deal-driven, momentum-supported zone rather than a value accumulation area. The 52-week range itself spans a 128% move from low to high, underscoring how violently sentiment has swung over the past year. Short-term momentum remains positive but has decelerated sharply: the 1-month change is +1.94% and the 3-month change is +87.5%, a massive divergence that reflects the July acquisition-driven spike followed by a flat consolidation. Relative strength versus SPY is +3.00 over 1 month, +84.46 over 3 months, and +39.50 over 1 year, confirming persistent outperformance, while the 1-month figure being only modestly positive suggests the stock is now range-bound rather than trending. The 3-month gain of 87.5% versus the 1-month gain of 1.94% indicates momentum has shifted from acceleration to a plateau, consistent with a merger-arbitrage dynamic. Key technical levels are well defined: support sits near the 52-week low of $3.265, with more immediate support around the $7.15-$7.18 shelf where the stock consolidated after its July gap, while resistance is the 52-week high of $7.45. A breakout above $7.45 would likely require a higher competing bid or deal sweetener, whereas a breakdown below $7.15 would signal deal-risk repricing or arbitrage unwinding. With a beta of 1.552, the stock is about 55% more volatile than the market, and a max drawdown of -48.06% shows how severe prior risk-off episodes have been, so position sizing should account for above-market volatility even with the deal anchor in place.

Beta

1.55

1.55x market volatility

Max Drawdown

-48.1%

Largest decline past year

52-Week Range

$3-$7

Price range past year

Annual Return

+55.7%

Cumulative gain past year

PeriodATAI ReturnS&P 500
1m+1.9%-1.6%
3m+87.5%+1.3%
6m+99.2%+13.9%
1y+55.7%+16.3%
ytd+89.9%+12.1%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

ATAI Fundamental Analysis

AtaiBeckley is a pre-revenue, clinical-stage company, and the available financial data reflects that: trailing EPS is -$0.71, net margin is -161.42%, and operating margin is -24.40%, with no quarterly financials, income statement, or cash flow data provided to establish a multi-quarter revenue trend. The absence of revenue segments and quarterly financials means the growth trajectory cannot be quantified from the supplied data, though the analyst consensus estimated revenue average of $215.2 million (range $117.8 million to $377.8 million) implies the market is modeling a future commercial ramp rather than current sales. The investment case therefore rests almost entirely on pipeline probability and the Lilly acquisition, not on demonstrated revenue growth. Profitability is deeply negative, with EPS of -$0.71, ROE of -297.49%, and ROA of -39.03%, though gross margin of 75.25% is high and typical of a biotech with licensing or partnership revenue rather than product sales. The operating margin of -24.40% is far less negative than the net margin of -161.42%, indicating that non-operating items, likely fair-value adjustments or impairments, are driving the bulk of the losses rather than core operating burn. Forward EPS estimates of -$0.196 (range -$0.389 to -$0.081) suggest analysts expect losses to narrow materially, consistent with either cost discipline or the pending acquisition eliminating standalone R&D spend. The balance sheet is exceptionally strong for a pre-revenue biotech: current ratio is 11.74 and debt-to-equity is just 0.0093, meaning the company carries almost no leverage and has ample short-term liquidity. However, with price-to-cash-flow of -9.02 and no positive free cash flow data provided, the company is not self-funding and has historically depended on external financing, which is typical for clinical-stage biotech. The near-zero debt and 11.7x current ratio substantially reduce solvency risk, but the negative ROE of -297.49% shows capital is being consumed rather than compounded, and the 2.84 short ratio indicates a meaningful short base that could amplify moves around deal news.

Quarterly Revenue

$1704000.0B

2026-06

Revenue YoY Growth

+137.0%

YoY Comparison

Gross Margin

87.4%

Latest Quarter

Free Cash Flow

$-133240840.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Open an Account, get $2 TSLA now!

Valuation Analysis: Is ATAI Overvalued?

Because net income is negative (EPS of -$0.71, net margin -161.42%), the PE ratio is not meaningful, and the appropriate primary metric is the price-to-sales ratio; ATAI trades at a PS of 226.59x and an EV/Sales of 560.02x, both of which are extreme and reflect a near-zero revenue base rather than a growth premium. The trailing PE of -1.41 and forward PE of -15.00 are both negative, and the gap between them implies the market expects losses to shrink substantially, consistent with the analyst forward EPS estimate of -$0.196 versus trailing -$0.71. The PEG ratio of -0.0066 is likewise not interpretable given negative earnings. On a peer-comparison basis, the PS of 226.59x and EV/Sales of 560.02x are far above what is typical for clinical-stage biotechnology, where pre-revenue names often trade on cash or pipeline value rather than sales; the premium is not justified by current fundamentals but by the acquisition premium embedded in the share price. The PB ratio of 4.18 is more moderate and suggests the market is valuing the company at roughly four times book, which for a biotech with minimal tangible assets implies significant intangible or deal value. Historical ratio data was not provided, so the current PS and PB cannot be benchmarked against the stock's own historical band; however, given the stock is at 98.5% of its 52-week range, it is almost certainly near the top of its historical valuation range, implying the market is pricing in optimistic deal-completion expectations rather than a value opportunity. The negative price-to-cash-flow of -9.02 and EV/EBITDA of -1.28 confirm that cash-flow-based valuation is not supportive, reinforcing that the current price is event-driven.

PE

-1.4x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

25.5x

Industry PE ~25.5x*

EV/EBITDA

-1.3x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are significant despite the strong balance sheet. The company is pre-revenue with trailing EPS of -$0.71, net margin of -161.42%, and operating margin of -24.40%, indicating ongoing cash burn. Although the current ratio of 11.74 and debt-to-equity of 0.0093 suggest ample liquidity and minimal leverage, the negative ROE of -297.49% shows capital is being consumed rather than compounded. The absence of quarterly financials and cash flow data makes it difficult to assess the sustainability of the burn rate, but the company has historically depended on external financing, which is typical for clinical-stage biotech. The pending acquisition by Eli Lilly may eliminate this risk if it closes, but until then, operational execution and trial outcomes remain critical.

Market and competitive risks are elevated due to the stock's extreme valuation and high volatility. The price-to-sales ratio of 226.59x and EV/Sales of 560.02x are far above typical clinical-stage biotech levels, leaving little room for disappointment. The beta of 1.552 means the stock is 55% more volatile than the market, and the max drawdown of -48.06% shows how severe prior selloffs have been. The short ratio of 2.84 indicates a meaningful short base that could amplify downside moves if deal news turns negative. Additionally, the stock is trading at 98.5% of its 52-week range, so any negative development could trigger a sharp reversion. The recent news highlights Eli Lilly's Q2 earnings beat, but there is no update on the acquisition timeline, leaving investors exposed to deal-completion risk.

Worst-case scenario: If the Eli Lilly acquisition fails to close due to regulatory hurdles, financing issues, or a change in strategic direction, the stock could rapidly reprice toward its pre-deal level. The pre-deal price was around $5.36 on July 15, 2026, implying a 27% decline from the current $7.35. In a more severe scenario, the stock could fall to its 52-week low of $3.265, representing a 55.6% loss from the current price. The analyst low target of $7.45 provides little cushion, and the high short interest could accelerate a selloff. Investors should be prepared for a potential drawdown of 27% to 55% if the deal breaks, making position sizing critical.

FAQ

The key risks are ranked by severity: first, deal failure risk, as the acquisition by Eli Lilly could be blocked or withdrawn, potentially causing a 27-55% decline to the pre-deal price of $5.36 or the 52-week low of $3.265. Second, valuation compression risk, given the extreme PS of 226.59x and EV/Sales of 560.02x, which could correct sharply if sentiment shifts. Third, financial risk, with negative EPS of -$0.71 and ROE of -297.49%, indicating ongoing cash burn despite a strong balance sheet. Fourth, market volatility risk, as beta of 1.552 and a max drawdown of -48.06% show the stock is highly sensitive to market swings. Each risk is significant, but deal failure is the most immediate.

The 12-month forecast has three scenarios: bull case (25% probability) targets $8.10-$9.25, assuming a competing bid or sweetened offer; base case (60% probability) targets $7.45-$8.10, assuming the deal closes as expected; bear case (15% probability) targets $3.265-$5.36, assuming deal failure. The base case is most likely, with the stock trading in a narrow range around the deal value. The key assumption is that Eli Lilly completes the acquisition without regulatory hurdles. If the deal breaks, the bear case could materialize quickly, making the risk-reward asymmetric.

ATAI appears overvalued on a fundamental basis, with a price-to-sales ratio of 226.59x and EV/Sales of 560.02x, far above typical clinical-stage biotech levels. These multiples are not supported by current revenue, as the company is pre-revenue with a net margin of -161.42%. However, the valuation reflects the acquisition premium from Eli Lilly, which provides a floor. Compared to its own history, the stock is at 98.5% of its 52-week range, suggesting it is near the top of its valuation band. The market is pricing in a high probability of deal completion, leaving little upside if the deal closes as expected.

ATAI is a good buy only for investors with a high risk tolerance and a merger-arbitrage strategy. The stock trades at $7.35, with a consensus target of $8.10 implying 10.2% upside, but the low target of $7.45 suggests limited room. The biggest downside risk is deal failure, which could send the stock to $5.36 or lower, a 27% drop. The strong balance sheet (current ratio 11.74) and the Eli Lilly acquisition provide some safety, but the extreme valuation (PS 226.59x) leaves little margin for error. For those comfortable with binary outcomes, it may be a buy; for others, it is a hold or avoid.

ATAI is suitable for short-term, event-driven investment rather than long-term holding. The stock is in a merger-arbitrage phase, with the price anchored to the acquisition value and limited upside to the analyst target of $8.10. The beta of 1.552 and max drawdown of -48.06% indicate high volatility, making it unsuitable for risk-averse long-term investors. There is no dividend (yield 0%), and the company is pre-revenue with negative earnings, so it does not fit a long-term growth or income portfolio. A suggested holding period is until the deal closes or a competing bid emerges, typically 6-12 months. After the deal, the stock may be delisted or converted, so long-term holding is not applicable.